may be leveraged to identify individuals at risk. While this likely would not currently impact the immediate treatment that one would receive, it would be intriguing to evaluate whether those most genomically vulnerable respond better or worse to early interventions, which may eventually have public health implications. Of note, PRS derived from GWAS of other psychopathologies (e.g., depression) do not currently account for nearly as much variance in disorder expression (Levine et al., 2014). However, it is expected that sample sizes for discovery GWAS will continue to increase, and with that, there will be greater precision in the effect sizes that are used as weights, and, consequently, the proportion of variance that they explain. Until then, it is critical that PRS are not construed as diagnostic tools but as ordinary predictors of risk, such as childhood trauma or family history, but with less explanatory power.
